Thursday, September 19, 2019

Thursday, September 19, 2019

U.S. FOOD AND DRUG ADMINISTRATION: Abciximab (ReoPro) Injection


U.S. Food and Drug Administration recently issued the following announcement. 

Abciximab (ReoPro) Injection

Status: Currently in Shortage

»Date first posted: 04/11/2018

»Therapeutic Categories: Cardiovascular

Janssen Biotech, Inc. (New 04/11/2018)

Company Contact Information: 800-586-7736

Presentation: 2mg/mL (NDC 57894-200-01)

Availability and Estimated Shortage Duration: Availability and estimated shortage duration: TBD

Shortage Reason (per FDASIA): Requirements related to complying with good manufacturing practices

Original source can be found here.

Organizations in this Story

U.S. Food and Drug Administration

More News

FDA Reporter